Spyre Therapeutics, Inc. (SYRE)
SYRENASDAQ-GSBiotechnology: Pharmaceutical Preparations
$104.48
-4.52 (-4.15%) today
Closed, Nov 10, 4:00 PM ET
- Market cap
- $9.92bn
- P/E
- –
- EPS, last 4 quarters
- $-2.74
- Dividend yield
- –
- Day range
- –
- 52-week range
- $21.63 to $110.64
- Average volume
- 1.28m
- Previous close
- $109.00
Analysts
14 coveringBuy13 buy, 1 hold, 0 sell
Targets a year out average $122.92, +17.6% from here
Earnings
next estimate $-0.8000Next report
Dec 2025
-6.1%
Mar 2026
-12.1%
Jun 2026
+49.3%
Sep 2026
-19.0%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$57.17m | -$45.64m | -$41.64m | -$105.72m |
| Net income | -$62.53m | -$69.00m | -$36.20m | -$96.12m |
News
8 latest- Spyre Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate UpdateFintel · Nov 3, 2026
- XBI, IOVA, SYRE, UTHR: ETF Inflow AlertBNK Invest · Oct 14, 2026
- Spyre Therapeutics Prices $350 Mln Public Offering Of Shares RTTNews · Oct 6, 2026
- Weekly Buzz: JNJ Wins FDA Nod; AXGN, HCWB Strike Deals; ROIV, AZN, GPCR Lead Clinical Trials RTTNews · Sep 11, 2026
- Spyre's Anti-IL-23 Antibody Meets Goal in Ulcerative Colitis StudyZacks · Sep 9, 2026
- Spyre Therapeutics Reports Positive Phase 2 SPY003 Data In Ulcerative Colitis RTTNews · Sep 8, 2026
- Spyre Therapeutics (SYRE) Down 16.6% Since Last Earnings Report: Can It Rebound?Zacks · Sep 3, 2026
- Weekly Buzz: GILD, ROIV Win FDA Nod; BHVN, LLY Strike Deal; SYRE Misses Monotherapy Goal RTTNews · Aug 28, 2026
The company
Spyre Therapeutics is a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients. Spyre's pipeline includes investigational extended half-life antibodies targeting 47, TL1A, IL-23, and IL-17A/F as well as rational combination programs.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- spyre.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.